PlasmaSELECT™-R 64

PlasmaSELECT™-R64 analyzes circulating tumor DNA for genetic alterations in cancer, eliminating the need for an invasive biopsy or tumor tissue. PlasmaSELECT™-R may also be used to evaluate sub-clonal mutations in tumor tissue, when available. PlasmaSELECT™-R evaluates a targeted panel of 64 well-characterized cancer genes. Cell-free DNA is extracted from plasma and prepared using proprietary methods that accommodate low abundance sample DNA. Samples are processed using a proprietary capture process and high coverage next-generation sequencing to allow tumor-specific (somatic) mutations, microsatellite instability (MSI) and translocations to be identified with a high sensitivity and specificity. Analyses for sequence mutations or rearrangements can be performed together or separately, depending on the specific alterations of interest.

PlasmaSELECT™-R 64 Key Metrics
Regions Analyzed 64 Genes
Sequencing Method Illumina next-generation sequencing
Bioinformatics Patented PARE, Digital Karyotyping and VariantDx
Turn-around Time 2-3 weeks
Sample Requirements Whole blood or plasma
Sample Input Required Two 10 ml tubes of peripheral whole blood; 6-10 ml plasma collected according to PGDx sample preparation instructions (>1-2ml for RUO)